Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The allergic response is a hypersensitive reaction of the immune system to substances (allergens) that are typically harmless to most people. This overreaction is mediated primarily by IgE antibodies, mast cells, and basophils, leading to the release of inflammatory mediators and a range of symptoms from mild irritation to life-threatening anaphylaxis. The process involves sensitization to an allergen, followed by activation upon re-exposure, and an effector phase where inflammatory mediators are released.
Varies depending on the specific drug. Antihistamines block histamine receptors. Corticosteroids reduce inflammation. Epinephrine reverses anaphylaxis by constricting blood vessels and opening airways. Omalizumab binds to IgE, preventing it from binding to mast cells and basophils. Allergen immunotherapy gradually desensitizes the immune system to specific allergens.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immune System (Allergic Response).